![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
Previous Article | Next Article 
Journal of Clinical Microbiology, June 1998, p. 1621-1624, Vol. 36, No. 6
Institute of Endemic Diseases, University of
Khartoum, Khartoum, Sudan,1 and
Department of Infectious Diseases,
Received 13 November 1997/Returned for modification 8 February
1998/Accepted 15 March 1998
Microscopy and PCR were compared for use in the diagnosis of
post-kala-azar dermal leishmaniasis (PKDL) in 63 patients.
Aspirates of lymph nodes (samples from 52 patients), skin (23 samples), and bone marrow (18 samples) were used. For 11 patients lymph node
aspiration could be repeated 6 months after they recovered from PKDL.
During active PKDL, PCR was positive for 42 of 52 (80.8%) lymph node
aspirates and 19 of 23 (82.7%) skin aspirates, whereas microscopy was
positive for only 9 of 52 (17.3%) lymph node aspirates and 7 of 23 (30.4%) skin aspirates. PCR was always positive when parasites were
seen by microscopy. When the results obtained with lymph node and skin
aspirates from the same patient (n = 16) were compared, there was complete agreement. Bone marrow samples were negative by microscopy and PCR for 16 patients and positive by both
methods for 1 patient; for one sample only the PCR was positive. PCR
confirmed the co-occurrence of visceral leishmaniasis and PKDL in one
patient and confirmed the suspicion of this co-occurrence in the other
patient. After recovery, no parasites were found by microscopy, but 2 of 11 (18.2%) samples were still positive by PCR. Thirty negative
controls were all found to be PCR negative, and 15 positive controls
were all PCR positive. Cross-reactions with Mycobacterium
leprae could be ruled out. In conclusion, PCR with inguinal lymph
node or skin aspirates is suitable for confirming the clinical
diagnosis of PKDL. In some patients, lymph node aspirates are probably
preferred because aspiration of material from the skin may leave scars.
Post-kala-azar dermal leishmaniasis
(PKDL) is a dermatropic form of leishmaniasis. It is found in areas
where Leishmania donovani is the causative agent of visceral
leishmaniasis (VL) (19). PKDL develops after the apparent
cure of VL and is characterized by the occurrence of macules, papules,
or nodules on the skin of the face, limbs, or trunk
(4). Although it was reported in the past that PKDL is far
less common in Africa than on the Indian subcontinent (16),
Zijlstra et al. (23) found that PKDL developed in more than
half of the cured VL patients in one study in eastern Sudan.
Methods for the diagnosis of VL often lack sensitivity or specificity
for the diagnosis of PKDL: (i) the number of parasites in skin smears
and biopsy specimens is often low or zero, thus requiring prolonged
searches by routine microscopy (4, 5); (ii) serological
tests are often positive due to the past occurrence of VL (6,
7); (iii) the leishmanin skin test (LST) may or may not be
positive (16); and (iv) cultures are often not positive and,
in the rural region where VL is endemic, cultures are prone to
contamination and often remain negative (12).
PKDL, in particular its nodular form, may easily be confused with a
number of dermatological conditions, of which leprosy is the most
important (4).
PKDL patients may be an important source of infection in the
transmission of VL (1, 18, 21).
In view of the low parasite load in clinical samples from PKDL patients
in combination with the possibility of confusion with other skin
disorders, particularly leprosy, there is an urgent need for more
sensitive diagnostic techniques. An increased sensitivity of microscopy
was reported when an immunoperoxidase technique with an anti-L.
donovani monoclonal antibody were used for the detection of the
parasite in skin biopsy specimens from PKDL patients (8).
Recently, several groups have shown that PCR is both a sensitive and a
specific method for the detection of Leishmania DNA in a
variety of clinical samples (2, 10, 13, 15, 19, 20).
Here we describe the application of PCR as a tool for use in the
diagnosis of PKDL in comparison with the use of microscopy and clinical
data in a longitudinal study in eastern Sudan, where PKDL is seen in
56% of all patients cured of VL (23). Leprosy also occurs
in this area.
Study area.
This investigation was carried out in eastern
Sudan in the villages of Um-Salala and Moshra Koka between April 1994 and April 1996. The total population (2,300 people) was screened twice
yearly to study the epidemiology of VL. People from other villages who presented during these screenings were investigated and were managed along the same lines as the populations of the two villages under investigation.
Clinical examination.
Demographic and clinical data were
recorded for each inhabitant as reported previously (22).
PKDL was diagnosed on clinical grounds and the aspect of the rash
(macular, nodular, or maculopapular), its distribution, and history of
spread (starting on the face around or on the nose, spreading to the
rest of the face, and then spreading to the shoulders, trunk, and upper
arms) and its relation to VL (23).
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Use of PCR for Diagnosis of Post-Kala-Azar
Dermal Leishmaniasis
ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
Collection of PCR material.
A total of 20 to 30 µl of
skin, lymph node, or bone marrow aspirate from PKDL patients was
collected on Whatman no. 3 filter paper. Each filter paper sample was
stored in a separate plastic bag at 
20°C.
1 for use as a positive control in the
PCR.
To exclude possible cross-reactions, we subjected two
Mycobacterium leprae PCR-positive skin aspirate specimens
from leprosy patients and 125 pg of M. leprae DNA to the
Leishmania PCR. Moreover, five skin aspirate specimens from
five microscopically positive PKDL patients and 1 ng of
Leishmania DNA were tested in the M. leprae
PCR; this PCR was performed as described by De Wit et al. (3).
DNA isolation. Skin, lymph node, or bone marrow aspirates on filter papers were put between two sheets of clean paper, and samples (punches) were punched out with a paper puncher. After punching of each sample, a clean sheet of paper was punched 10 to 12 times in order to prevent DNA contamination from one sample to the next (13). The same paper puncher was used throughout the investigation, and for every batch of 35 patient samples, 10 negative controls and 3 positive controls were randomly distributed to examine for contamination and inhibition.
DNA was isolated as described previously (10, 13). Two punches (equaling approximately 15 µl of aspirate) were placed in 250 µl of lysis buffer (50 mM NaCl, 50 mM Tris-HCl [pH 7.4], 10 mM EDTA, 1% [vol/vol] Triton X-100, 200 µg of proteinase K per ml), and the mixture was incubated overnight at 60°C. The samples were then subjected to phenol-chloroform extraction, precipitated with ethanol, and redissolved in 50 µl of TE buffer (10 mM Tris-HCl, 1 mM EDTA [pH 7.5]).PCR amplification. PCR amplification was carried out as described previously (13). Briefly, 5 µl of isolated DNA was added to 45 µl of a PCR mixture containing 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 4 mM MgCl2, each deoxynucleoside triphosphate at a concentration of 250 µM, 500 µM dUTP, 0.5 U of Taq polymerase, 0.5 U of uracil nucleotide glycosylase, 100 pmol of primer 174 (5'-GGTTCCTTTCCTGATTTACG-3'), and 100 pmol of primer 789 (5'-GGCCGGTAAAGGCCGAATAG-3').
The samples were preincubated at 50°C for 5 min, followed by initial denaturation at 94°C for 10 min and 38 cycles consisting of denaturation at 94°C for 75 s, annealing at 60°C for 1 min, and extension at 72°C for 2 min. The amplification reactions were visualized on a 2% agarose gel; a 100-bp DNA ladder (Pharmacia, Uppsala, Sweden) was used as a marker. Samples were scored as positive when a PCR product of 560 bp could be detected.Dilution series. Differences in the Leishmania DNA concentrations in lymph node aspirates from VL patients and PKDL patients were detected by making 10-fold dilution series of DNA from the lymph node samples and subjecting these to PCR as described above.
Statistical analysis. McNemar's chi-square test (contingency tables) was used throughout.
| |
RESULTS |
|---|
|
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
|
|---|
Control experiments. We have tested a total of 104 clinical samples from PKDL patients, 15 positive controls, and 30 negative controls. All negative controls were negative by PCR, whereas all positive controls were positive. Control samples containing M. leprae were negative by the Leishmania PCR, as were the samples containing Leishmania by the M. leprae PCR. In conclusion, no contamination, inhibition, or cross-reaction was detected.
Lymph node aspirates taken during PKDL. Lymph node aspirates from 52 PKDL patients were subjected to PCR and microscopy. A comparison of the results is given in Table 1. PCR detected Leishmania in lymph node aspirates significantly more often than microscopy did (P < 0.000001).
|
Lymph node aspirates taken 6 months after PKDL. The data in Table 2 indicate that there was no significant difference in the results between PCR and microscopy with lymph node aspirates taken 6 months after the patients recovered from PKDL (P > 0.05).
|
Slit skin smears taken during PKDL. Slit skin smears from PKDL patients were subjected to PCR and microscopy. A comparison of the results is given in Table 3. PCR detected the presence of Leishmania significantly more often than microscopy did (P = 0.001).
|
Bone marrow aspirates taken during PKDL. Bone marrow aspirates from 18 PKDL patients were subjected to PCR and microscopy. One of 18 samples was positive by microscopy and PCR, and one sample was PCR positive and microscopy negative. The remaining 16 samples were negative by both methods.
Comparison of PCR with lymph node and slit skin smears taken from the same patient. For 16 patients a lymph node aspirate and skin smear material could concurrently be examined by PCR. For 13 of these 16 patients the PCR of a lymph node aspirate and slit skin smear were both positive, whereas for the other 3 patients PCR of both types of samples was negative.
Comparison of PCRs with material from bone marrow, lymph node, and skin taken from PKDL patients. For PKDL patients, PCR detects Leishmania significantly more often in slit skin smear and lymph node aspirates than in bone marrow aspirates (P < 0.000001). The results in Tables 1 and 3 reveal that there is no significant difference (P = 1) between the results of PCR with lymph node aspirates and slit skin smears. When comparing the results of PCRs with slit skin smear and lymph node aspirates taken from the same PKDL patient, we found a 100% agreement (see above).
| |
DISCUSSION |
|---|
|
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
|
|---|
PKDL frequently occurs after the treatment of active VL in India (18) and Sudan (23) but occurs less frequently in Kenya (11). Sporadic cases have been reported from China (9) and the Mediterranean area, where L. infantum is the causative agent of VL. Recently, the first case of PKDL in a human immunodeficiency virus-infected person from Spain has been reported (17).
PKDL can easily be confused with a number of skin disorders. Clinical similarities between the skin lesions of PKDL and leprosy may lead to diagnostic difficulties, especially in areas where the diseases are coendemic (4). The microscopic detection of parasites in PKDL lesions is impeded by the limited sensitivity of microscopy (4, 5). Clinical diagnosis may be problematic for patients in whom there is a long interval between active VL and the development of PKDL.
We have evaluated the use of Leishmania PCR with different clinical materials for the diagnosis of PKDL. First, we investigated the specificity of the Leishmania PCR with M. leprae DNA and samples from leprosy patients. No cross-reactivity was found.
PCR and microscopy were both negative for the majority of the bone marrow aspirates taken from PKDL patients. Of the two patients who were PCR positive, one was diagnosed as having a para-kala-azar dermal leishmaniasis case (the simultaneous occurrence of VL and PKDL), and in the other patient the co-occurrence of VL and PKDL was suspected and was confirmed by PCR.
In a previous study, we found all 13 bone marrow aspirate specimens from VL patients to be positive by PCR (13). In contrast, during the present study we found only 2 of 18 bone marrow aspirate specimens from PKDL patients to be positive by PCR. This significant difference (P < 0.00001) is probably due to the fact that the parasites are cleared from the bone marrow as cell-mediated immunity develops during or after treatment of VL (24) and apparently are no longer present during PKDL.
It was shown previously that microscopy of lymph node aspirates from PKDL patients is of limited sensitivity (23). Here we report that PCR with these lymph node aspirates is a sensitive method by which parasites can be detected more frequently than by microscopy (P < 0.000001).
Indian researchers found that LST-negative PKDL patients were more likely to be positive by microscopy than LST-positive PKDL patients (16). By PCR, we also found that LST-negative persons were positive by PCR (27 of 29) significantly more often than LST-positive individuals (10 of 17) (P = 0.0078). For LST-positive patients the cellular immune response is better developed and will kill some of the parasites. Therefore, one may expect that LST-positive patients generally have lower parasite levels than LST-negative patients and therefore more often tend to be negative by PCR.
When studying VL patients, we found 33 of 38 lymph node aspirate specimens to be positive by PCR (13). This is not significantly different from the results obtained with lymph node aspirates from PKDL patients (42 of 52 of whom were positive). On the other hand, comparison of microscopic detection of Leishmania in lymph node aspirates from VL patients (31 of 38 of whom were positive) and PKDL patients (9 of 52 of whom were positive) differed significantly (P < 0.0000001). The results of the control experiments together with the results of PCR and microscopy for VL patients indicate that the PCR results with lymph node aspirates from PKDL patients are not due to false-positive results. Using 10-fold dilution series of DNA from isolates from VL and PKDL patients, we found that lymph node aspirates from PKDL patients contained relatively low amounts of Leishmania DNA compared to the amounts in the lymph node aspirates from VL patients. The low concentration of the parasite may also explain the discrepancy between PCR and microscopy results for lymph node aspirates from PKDL patients.
Comparison of PCR and microscopy results for lymph node aspirates taken 6 months after recovery from PKDL showed that there was no significant difference, and the results of both tests tended to be negative, as may be expected. However, by PCR we still found two lymph node aspirates to be positive. Since PCR in patients who previously had VL is predictive of the future development of PKDL (14), these patients should be monitored closely for a recurrence of PKDL.
In PKDL patients Leishmania parasites are scanty and difficult to demonstrate during the stage when the skin lesions are hypopigmented, but their numbers gradually increase with the progress toward the nodular stage of the disease (5). In this study, Leishmania was detected in significantly more skin aspirates taken from PKDL patients by PCR than by microscopy. However, we found no significant correlation between the severity or distribution of the disease and the percentage of PCR-positive patients (data not shown). This is probably due to the high number of PCR-positive patients.
There was no significant difference in the PCR results obtained with lymph node aspirates (42 of 52 were positive; sensitivity, 81%) and skin aspirates (19 of 23 were positive; sensitivity, 83%) from PKDL patients before treatment. This was confirmed when we compared PCR with pairs of lymph node and skin aspirates taken from 16 patients.
In conclusion, we have demonstrated that PCR with either lymph node or skin aspirates is more sensitive than microscopy for the diagnosis of PKDL; this may be due to the often low concentration of the parasite. For the diagnosis of PKDL one can use either lymph node or skin material. Since PKDL is often confined to the face, one may prefer to take lymph node material rather than skin material because the aspiration procedure may leave scars.
| |
ACKNOWLEDGMENTS |
|---|
This work was financially supported by EU grant TS3*-CT93-0245.
We thank Eltahir Fadul, Ahmed Abdel Majid, and Khamis Abdu for collecting samples in the field and Sjoukje Kuijper for performing the M. leprae PCR. We gratefully acknowledge the logistical support of the MSF Holland office in Khartoum, Sudan.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Royal Tropical Institute (KIT), Department of Biomedical Research, Meibergdreef 39, 1105 AZ Amsterdam, The Netherlands. Phone: (31)-20-5665441. Fax: (31)-20-6971841. E-mail: bo{at}mail.support.nl.
| |
REFERENCES |
|---|
|
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
|
|---|
| 1. | Addy, M., and A. Nandy. 1992. Ten years of kala-azar in West-Bengal, part I. Did post-kala-azar dermal leishmaniasis initiate the outbreak in 24-Parganas? Bull. W. H. O. 70:341-346[Medline]. |
| 2. | De Bruijn, M. H. L., and D. C. Barker. 1992. Diagnosis of New World leishmaniasis: specific detection of species of the Leishmania braziliensis complex by amplification of kinetoplast DNA. Acta Trop. 52:45-58[Medline]. |
| 3. |
De Wit, M. Y. L.,
J. T. Douglas,
J. McFadden, and P. R. Klatser.
1993.
Polymerase chain reaction for the detection of Mycobacterium leprae in nasal swab specimens.
J. Clin. Microbiol.
31:502-506 |
| 4. | El Hassan, A. M., H. W. Ghalib, E. E. Zijlstra, I. A. Eltoum, M. Satti, M. S. Ali, and H. M. A. Ali. 1992. Post kala-azar dermal leishmaniasis in the Sudan: clinical features, pathology and treatment. Trans. R. Soc. Trop. Med. Hyg. 86:245-248[Medline]. |
| 5. | Ghosh, M. K., A. Nandy, M. Addy, T. K. Maitra, and A. C. Ghose. 1995. Subpopulations of T lymphocytes in peripheral blood, dermal lesions and lymph nodes of post kala-azar dermal leishmaniasis patients. Scand. J. Immunol. 41:11-17[Medline]. |
| 6. | Haldar, J. P., K. C. Saha, and A. C. Ghose. 1981. Serological profiles in Indian post kala-azar dermal leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 75:514-517[Medline]. |
| 7. | Harith, A. E., S. Chowdury, A. Al-Masum, S. Semiao-Santos, P. K. Das, S. Akhter, J. C. M. Vetter, and I. Haq. 1996. Reactivity of various leishmanial antigens in a direct agglutination test and their value in differentiating post-kala azar dermal leishmaniasis from leprosy and other skin conditions. J. Med. Microbiol. 44:141-146[Abstract]. |
| 8. | Ismail, A., A. Kharazmi, H. Permin, and A. M. El Hassan. 1997. Detection and characterization of Leishmania in tissues of patients with post kala-azar dermal leishmaniasis using a specific monoclonal antibody. Trans. R. Soc. Trop. Med. Hyg. 91:283-285[Medline]. |
| 9. | Leng, Y.-J. 1982. A review of kala-azar in China from 1949 to 1959. Trans. R. Soc. Trop. Med. Hyg. 76:531-537[Medline]. |
| 10. | Meredith, S. E. O., E. E. Zijlstra, G. J. Schoone, C. C. M. Kroon, G. J. J. M. Van Eys, K. U. Schaeffer, A. M. El-Hassan, and P. G. Lawyer. 1993. Development and application of the polymerase chain reaction for the detection and identification of Leishmania parasites in clinical material. Arch. Inst. Pasteur Tunis 70:419-431[Medline]. |
| 11. | Muigai, R., G. S. Gachihi, C. N. Oste, J. B. O. Were, P. M. Nyakundi, C. N. Chunge, G. Kirigi, and J. R. Rashid. 1991. Post kala-azar dermal leishmaniasis: the Kenyan experience. East Afr. Med. J. 68:801-806[Medline]. |
| 12. | Oskam, L., F. Pratlong, E. E. Zijlstra, C. C. M. Kroon, J.-P. Dedet, P. A. Kager, G. Schönian, H. W. Ghalib, A. M. El-Hassan, and S. E. O. Meredith. 1998. Biochemical and molecular characterization of Leishmania parasites isolated from an endemic focus in eastern Sudan. Trans. R. Soc. Trop. Med. Hyg. 92:120-122[Medline]. |
| 13. | Osman, O. F., L. Oskam, E. E. Zijlstra, N. C. M. Kroon, G. J. Schoone, E. A. G. Khalil, A. M. El-Hassan, and P. A. Kager. 1997. Evaluation of the polymerase chain reaction for the diagnosis of visceral leishmaniasis. J. Clin. Microbiol. 35:2454-2457[Abstract]. |
| 14. | Osman, O. F., P. A. Kager, E. E. Zijlstra, A. M. El-Hassan, and L. Oskam. 1997. Use of PCR on lymph-node samples as test of cure of visceral leishmaniasis treatment. Ann. Trop. Med. Parasitol. 91:845-850[Medline]. |
| 15. | Piarroux, R., R. Azaiez, A. M. Lossi, P. Reynier, F. Muscatelli, F. Gambarelli, M. Fontes, H. Dumon, and M. Quilici. 1993. Isolation and characterization of a repetitive DNA sequence from Leishmania infantum: development of a visceral leishmaniasis polymerase chain reaction. Am. J. Trop. Med. Hyg. 49:364-369. |
| 16. | Ramesh, V., and A. Mukherjee. 1995. Post kala-azar dermal leishmaniasis. Int. J. Dermatol. 43:85-91. |
| 17. | Rios-Buceta, L., G. F. Buezo, P. F. Peñas, E. Dauden-Tello, M. Aragües-Montañes, J. Fraga-Fernandez, and A. Garcia-Diez. 1996. Post-kala-azar dermal leishmaniasis in an HIV patient. Int. J. Dermatol. 35:303-304[Medline]. |
| 18. | Thakur, C. P., and K. Kumar. 1992. Post kala-azar dermal leishmaniasis: a neglected aspect of kala-azar control programmes. Ann. Trop. Med. Parasitol. 86:355-359[Medline]. |
| 19. | Uliana, S. R., M. H. Affonso, E. P. Camargo, and L. M. Floeter-Winter. 1991. Leishmaniasis: genus identification based on a specific sequence of the 18S ribosomal RNA sequence. Exp. Parasitol. 72:157-163[Medline]. |
| 20. | Van Eys, G. J. J. M., G. J. Schoone, N. C. M. Kroon, and S. B. Ebeling. 1992. Sequence analysis of a small subunit ribosomal RNA gene and its use for detection and identification of Leishmania parasites. Mol. Biochem. Parasitol. 51:133-142[Medline]. |
| 21. | World Health Organization. 1990. Control of the leishmaniases. Report of a WHO expert committee. WHO Technical Report Series 793. World Health Organization, Geneva, Switzerland. |
| 22. | Zijlstra, E. E., A. M. El-Hassan, A. Ismael, and H. W. Ghalib. 1994. Endemic kala-azar in eastern Sudan: a longitudinal study on the incidence of clinical and subclinical infection and post-kala-azar dermal leishmaniasis. Am. J. Trop. Med. Hyg. 51:826-836. |
| 23. | Zijlstra, E. E., A. M. El-Hassan, and A. Ismail. 1995. Endemic kala-azar in eastern Sudan: post kala-azar dermal leishmaniasis. Am. J. Trop. Med. Hyg. 52:299-305. |
| 24. | Zijlstra, E. E., A. M. Siddig, A. M. El-Hassan, I. A. El-Toum, M. Satti, H. W. Ghalib, and P. A. Kager. 1992. Kala-azar: a comparative study of parasitological methods and the direct agglutination test in diagnosis. Trans. R. Soc. Trop. Med. Hyg. 86:505-507[Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. |
|---|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|
